GSK and Medicago announce collaboration to develop a novel adjuvanted COVID-19 candidate vaccine

GSK and Medicago announced a collaboration to develop and evaluate a COVID-19 candidate vaccine combining Medicago’s recombinant Coronavirus Virus-Like Particles (CoVLP) with GSK’s pandemic adjuvant system. CoVLPs mimic the structure of the virus responsible for COVID-19 disease, allowing them to be recognised by the immune system. Use of an adjuvant can be of particular importance […]

Continue Reading

Merck initiates first clinical trial of TLR7 and 8 inhibitor as a potential treatment for severe symptoms of COVID-19 infection

Merck, a leading science and technology company, announced the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug application (IND) for M5049 for the treatment of patients with Covid-19 pneumonia. Merck will initiate a Phase II randomized, controlled clinical study evaluating the safety and efficacy of M5049 in this patient population. M5049 […]

Continue Reading

Novartis resolves legacy litigation matters, finalizing settlement of speaker program litigation with Government in the US

Novartis has finalized its previously disclosed agreement with the US Attorney’s Office for the Southern District of New York, the New York State Attorney General, and relator Oswald Bilotta resolving a civil suit challenging speaker programs and other promotional events conducted from 2002 through 2011 by Novartis Pharmaceuticals Corporation in the US. As part of […]

Continue Reading

Pfizer and BioNTech announce early positive data from an ongoing Phase 1/2 study of mRNA-based vaccine candidate against SARS-CoV-2

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced preliminary data from the most advanced of four investigational vaccine candidates from their BNT162 mRNA-based vaccine program, Project Lightspeed, against SARS-CoV-2, the virus causing the current global pandemic. The BNT162 program is evaluating at least four experimental vaccines, each of which represents a unique […]

Continue Reading

GSK COVID-19 vaccine development collaboration with Clover Biopharmaceuticals begins clinical trials

GSK’s scientific collaboration with Clover Pharmaceuticals to develop an adjuvanted COVID-19 vaccine has entered into human clinical trials. Clover announced the initiation of a Phase 1 clinical study evaluating the company’s COVID-19 S-Trimer vaccine (SCB-2019) in combination with GSKs pandemic adjuvant system. The study initiation follows promising preclinical results which demonstrated the beneficial effect of […]

Continue Reading

Novartis research shows technology talent increasingly drawn to pharma industry since COVID-19, to solve healthcare challenges

Novartis revealed the healthcare and pharma industry has emerged as a desired career destination for tech talent during the COVID-19 pandemic, in the Powerful Pairing research report launched today. The research – which covered 2,502 tech professionals in the US, UK, Germany, China and India, conducted between May and June 2020 – targeted respondents from […]

Continue Reading

Sanofi and Translate Bio expand collaboration to develop mRNA vaccines across all infectious disease areas

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, have agreed to expand their existing 2018 collaboration and license agreement to develop mRNA vaccines for infectious diseases. The expansion of this agreement will further unite Translate Bio’s expertise and knowledge from more than […]

Continue Reading

Novartis discontinues hydroxychloroquine clinical trial based on slow enrollment, remains committed to pandemic research efforts

Novartis has made the decision to stop and discontinue its sponsored HCQ clinical trial for COVID-19 due to acute enrollment challenges that have made trial completion infeasible. The recruitment challenge facing our HCQ trial has made it unlikely that the clinical team will be able to collect meaningful data in a reasonable timeframe to determine […]

Continue Reading

Bayer supports “The Challenge Initiative” of Johns Hopkins Bloomberg School of Public Health with 10 million USD

Today Bayer announced the support of “The Challenge Initiative” (“TCI” hereafter) with a payment of 10 million USD. Hosted at the Johns Hopkins Bloomberg School of Public Health, the initiative provides women and girls living in urban poverty in cities in Africa and Asia with family planning and reproductive health solutions. TCI is led by […]

Continue Reading